Vivo Capital LLC Has $40.66 Million Position in Bright Minds Biosciences Inc. $DRUG

Posted by Geri Gentry on Jul 31st, 2026

Vivo Capital LLC increased its stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG – Free Report) by 11.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 557,172 shares of the company’s stock after buying an additional 55,555 shares during the period. Bright Minds Biosciences makes up 3.4% of Vivo Capital LLC’s holdings, making the stock its 10th biggest holding. Vivo Capital LLC owned 0.06% of Bright Minds Biosciences worth $40,657,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its position in Bright Minds Biosciences by 11.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,284,324 shares of the company’s stock valued at $93,518,000 after acquiring an additional 128,329 shares in the last quarter. Braidwell LP raised its stake in shares of Bright Minds Biosciences by 6.8% in the fourth quarter. Braidwell LP now owns 324,358 shares of the company’s stock worth $25,313,000 after acquiring an additional 20,673 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of Bright Minds Biosciences during the fourth quarter worth approximately $17,961,000. Balyasny Asset Management L.P. lifted its position in shares of Bright Minds Biosciences by 20.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 225,412 shares of the company’s stock worth $17,591,000 after purchasing an additional 38,490 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Bright Minds Biosciences by 153.6% during the fourth quarter. Millennium Management LLC now owns 194,437 shares of the company’s stock worth $15,174,000 after purchasing an additional 117,756 shares in the last quarter. Institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Trading Up 5.0%

Shares of NASDAQ DRUG opened at $74.63 on Friday. The firm has a market capitalization of $726.15 million, a PE ratio of -30.59 and a beta of -5.34. Bright Minds Biosciences Inc. has a 1 year low of $31.80 and a 1 year high of $123.75. The firm’s 50-day moving average is $71.39 and its 200-day moving average is $77.86.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.06. As a group, equities research analysts anticipate that Bright Minds Biosciences Inc. will post -4.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Bright Minds Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, July 4th. Jefferies Financial Group initiated coverage on Bright Minds Biosciences in a report on Monday, April 13th. They set a “buy” rating and a $145.00 price objective on the stock. Zacks Research upgraded Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating and issued a $145.00 target price on shares of Bright Minds Biosciences in a research note on Monday, June 1st. Finally, Piper Sandler restated an “overweight” rating and set a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat.com, Bright Minds Biosciences currently has an average rating of “Buy” and an average target price of $143.83.

Get Our Latest Stock Analysis on DRUG

Bright Minds Biosciences Company Profile

(Free Report)

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.